Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
about
What does schizophrenia teach us about antipsychotics?The additional therapeutic effect of group music therapy for schizophrenic patients: a randomized study.Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks.On the Complexity of Brain Disorders: A Symptom-Based Approach.Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.Negative symptoms in schizophrenia: a review.Treatments in context: transcranial direct current brain stimulation as a potential treatment in pediatric psychosisMethodological issues in negative symptom trialsNegative symptoms and concomitant attention deficits in schizophrenia: associations with prospective assessments of anxiety, social dysfunction, and avoidant coping.An Integrative Perspective on the Role of Dopamine in SchizophreniaAdjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features.Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia.Brain in flames - animal models of psychosis: utility and limitationsYoga therapy for Schizophrenia.Therapeutic efficacy of add-on yogasana intervention in stabilized outpatient schizophrenia: Randomized controlled comparison with exercise and waitlistMeasuring negative symptoms in patients with schizophrenia: reliability and validity of the Korean version of the Motivation and Pleasure Scale-Self-ReportLongitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.A review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia.Drugs in development for the treatment of schizophrenia.Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.Efficacy Towards Negative Symptoms and Safety of Repetitive Transcranial Magnetic Stimulation Treatment for Patients with Schizophrenia: A Systematic Review.A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.Conceptualization and treatment of negative symptoms in schizophrenia.A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophreniaMetacognitive Reflection and Insight Therapy (MERIT) with a Patient with Persistent Negative Symptoms.Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels.Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study.D1 receptor antagonist-induced long-term depression in the medial prefrontal cortex of rat, in vivo: an animal model of psychiatric hypofrontality.Repetitive transcranial magnetic stimulation as new technique for treatment of negative symptoms of schizophrenia.Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways.Effects of ketamine on brain function during smooth pursuit eye movements.Neuroprotective effects of the ethanol stem bark extracts of Terminalia ivorensis in ketamine-induced schizophrenia-like behaviors and oxidative damage in mice.Natural Medicines for Psychotic Disorders: A Systematic Review.N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.Societal participation: examining the impact of a rehabilitation approach for young people with schizophrenia.Accumbens dopamine D2 receptors increase motivation by decreasing inhibitory transmission to the ventral pallidum.
P2860
Q26823906-6449915F-434C-45C8-B5D1-D1BD73D6A632Q30365013-444BE25F-160B-4D89-9909-BCFD27180B39Q30370326-324DCB9F-3EBE-4491-96BA-E14CD61456E1Q30389213-2B57DB37-A467-43CC-B885-99AE02575AC3Q30491856-75F97302-5670-4F23-B009-305617AD5BDBQ33364180-B2435371-7BA1-4464-A9E7-D349CDCC5665Q33778750-BEE5D0BD-1EAE-49DB-B22F-772AD27D3921Q33804836-1EECADE7-2735-4438-B21B-A3C3645948CDQ33831204-42676F55-E8C0-42AE-B929-ADF7E02EE753Q33839379-3CC9F280-5B7F-4FFA-9986-F195B9BF7A7EQ34350145-66D12AB7-94CC-44E1-96FE-E0ACC1A36A98Q34393630-36D460CD-DEA8-4168-9492-847D314F2D24Q34672123-8D24F627-DA32-4D72-ABDE-6057990BE229Q35071909-7C4FB129-8321-4B14-9924-21503D52E0C1Q35166963-66CC261F-9D62-4EA1-BC26-596D72C6E6C2Q35683865-D61788EB-ABFB-4458-890B-C54681E0653FQ36134448-CD4EFFC7-2707-4037-9885-0DA04ACDFA77Q36440394-DB16A55C-36C2-4BFA-ABAC-5915F5B094D6Q36908425-404F449C-A198-4717-9DF6-9B5345176399Q37010792-474E8E75-A34B-4F58-B905-BE851E4E470BQ37272791-5DBE4E53-8DC2-4A09-A277-AD45B707B21AQ37546125-930EE0D7-16F9-45D8-A5E9-E59FAD7C8204Q37862242-8BD7C64A-B12F-4EDD-84EC-9C501E467EFAQ38369285-F114E1F6-9FD2-4844-A9FB-8C25E29E0C5AQ38630825-50F58416-558B-4894-A3A3-920F4822F6E5Q38718345-48E1CB34-7763-416D-A276-A3C841CEEC13Q39178474-B520BF85-FCAB-4DAE-AB32-EF490E18DDABQ41442026-A003D537-4CF7-4F2C-9F0A-613439A5549EQ41445097-A3585BDC-5CE0-423E-84B7-86540A73C3CBQ42099006-D12F306B-487C-46F9-8C82-FE10BD2F1FF4Q42615753-3565FEB1-FB16-40CC-A90E-4B4717D87A7CQ46477524-ED115F3F-AA08-480E-BB7A-10219486BF4BQ46946058-335680EC-798F-424F-8740-55B232C95D45Q47970067-6AF8CD50-9AFC-43AB-90B3-70FD01F2D1FFQ48656998-6A4B2224-BE33-4A6E-B45D-4BA5DF5A49D8Q48702321-22253242-7A76-4057-9D69-C89BC8259B5AQ49363880-C182B564-F835-476F-B4E6-A8A1EF7D52B7Q50281040-40520104-C1E1-4E5F-8A17-0496B2DF063AQ50774375-D34AD00F-5224-4CF9-AFE0-423C9246BFD9Q51740117-44160461-E5E4-43A2-A823-45D06F7C7E76
P2860
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@ast
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@en
type
label
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@ast
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@en
prefLabel
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@ast
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@en
P2860
P1476
Pharmacological treatment of n ...... tic opportunity or cul-de-sac?
@en
P2093
P2860
P304
P356
10.1111/J.1600-0447.2007.00992.X
P407
P577
2007-02-01T00:00:00Z